High impact information on Factor XIII Deficiency

• Differential binding of plasminogen to crosslinked and noncrosslinked fibrins: its significance in hemostatic defect in factor XIII deficiency [1].
• Factor XIII deficiency associated with valproate treatment [2].
• Because of its higher pH, urea will not activate pepsinogen and is therefore a better agent to screen factor XIII deficiencies [3].
• In an Italian patient with severe factor XIII deficiency, a novel mutation, Y283C (TAT to TGT), was identified heterozygously by nucleotide sequencing analysis in exon VII of the gene for the A subunit [4].
• ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Study Group [5].

Chemical compound and disease context of Factor XIII Deficiency

• Presumptive diagnosis of factor XIII deficiency was made with a clot solubility screening test and confirmation was accomplished by demonstrating the absence of factor XIII by latex agglutination [6].

Biological context of Factor XIII Deficiency

• Surgery in severe factor XIII deficiency: report of a case of epilepsy neurosurgery and review [7].

Gene context of Factor XIII Deficiency

• In 3 Chinese families, hereditary coagulation factor XIII deficiency was diagnosed on the basis of the clinical syndrome and solubility of fibrin clot in 5 mol/L urea [8].
• A novel compound heterozygous mutation in the F13A gene causing hereditary factor XIII deficiency in a Chinese family [9].

References